| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CK12 |
| Uniprot No | P78368 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-415aa |
| 氨基酸序列 | MDFDKKGGKGETEEGRRMSKAGGGRSSHGIRSSGTSSGVLMVGPNFRVGKKIGCGNFGELRLGKNLYTNEYVAIKLEPIKSRAPQLHLEYRFYKQLSATEGVPQVYYFGPCGKYNAMVLELLGPSLEDLFDLCDRTFTLKTVLMIAIQLITRMEYVHTKSLIYRDVKPENFLVGRPGTKRQHAIHIIDFGLAKEYIDPETKKHIPYREHKSLTGTARYMSINTHLGKEQSRRDDLEALGHMFMYFLRGSLPWQGLKADTLKERYQKIGDTKRATPIEVLCENFPEEMATYLRYVRRLDFFEKPDYDYLRKLFTDLFDRSGFVFDYEYDWAGKPLPTPIGTVHTDLPSQPQLRDKTQPHSKNQALNSTNGELNADDPTAGHSNAPITAPAEVEVADETKCCCFFKRRKRKSLQRHK |
| 预测分子量 | 47,4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条与CK12(角蛋白12)重组蛋白相关的参考文献摘要示例：
---
1. **文献名称**：*Expression and Purification of Recombinant Human Keratin 12 in Escherichia coli*
**作者**：Smith A, et al.
**摘要**：本研究成功构建了人源角蛋白12(KRT12)的重组表达载体，利用大肠杆菌系统进行表达，并通过亲和层析纯化获得高纯度蛋白。该重组蛋白可用于后续角膜上皮细胞分化机制的研究。
2. **文献名称**：*Functional Analysis of Mutant Keratin 12 in Meesmann Corneal Dystrophy Using Recombinant Protein Models*
**作者**：Chen L, et al.
**摘要**：通过昆虫细胞表达系统制备野生型和突变型KRT12重组蛋白，发现特定突变导致蛋白稳定性下降，揭示了Meesmann角膜营养不良的分子病理机制。
3. **文献名称**：*Development of a CK12-Based Biomarker Assay for Ocular Surface Disorders*
**作者**：Wang X, et al.
**摘要**：利用哺乳动物细胞表达的重组CK12蛋白开发ELISA检测方法，证实其在干眼症患者泪液中表达异常，为临床诊断提供了潜在生物标志物。
---
注：以上文献为示例性质，实际引用需根据具体研究内容检索数据库(如PubMed、Web of Science)获取。若需精确文献，建议补充关键词或研究背景进一步筛选。
**Background of CK12 Recombinant Protein**
CK12. or cytokeratin 12. is a type I intermediate filament protein primarily expressed in the corneal epithelium, where it plays a critical role in maintaining cellular structural integrity and mechanical stability. As a member of the keratin family, CK12 forms heteropolymers with its type II partner, cytokeratin 3 (CK3), to create a resilient cytoskeletal network essential for protecting ocular surfaces from physical stress and damage. Mutations in the *KRT12* gene, which encodes CK12. are linked to Meesmann epithelial corneal dystrophy (MECD), a rare hereditary disorder characterized by fragile corneal epithelium, microcysts, and photophobia.
Recombinant CK12 protein is produced using biotechnological methods, often involving the expression of the *KRT12* gene in heterologous systems like *E. coli*, yeast, or mammalian cell lines. These systems enable large-scale production of CK12 with high purity and specificity, essential for functional studies. Post-translational modifications (e.g., phosphorylation) critical for its biological activity can be better replicated in eukaryotic expression systems.
The availability of recombinant CK12 has advanced research into corneal biology and disease mechanisms. It serves as a tool to study keratin filament assembly, protein-protein interactions, and the pathological effects of *KRT12* mutations. Additionally, recombinant CK12 is utilized in drug screening platforms to identify potential therapeutics for MECD and other corneal disorders. Its application extends to diagnostic development, including antibody production for detecting CK12 expression levels in clinical samples.
Beyond ophthalmology, CK12 recombinant protein contributes to broader studies on epithelial cell differentiation, wound healing, and keratin-related pathologies. Its role in modeling diseases *in vitro* and validating gene-editing therapies (e.g., CRISPR-Cas9) underscores its importance in translational research. As interest in personalized medicine grows, recombinant CK12 remains a vital resource for unraveling genotype-phenotype correlations and developing targeted treatments for keratinopathies.
×
